NEW YORK, September 29, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: Biogen Inc. (NASDAQ: BIIB), Depomed, Inc.
(NASDAQ: DEPO), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA),
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX),
Amicus Therapeutics, Inc. (NASDAQ: FOLD). On Monday, September 28, 2015, NASDAQ ended at
4,543.97 down 3.04%, Dow Jones declined 1.92%, to finish the day at
16,001.89, and the S&P closed at 1,881.77, down 2.57%. Register
for your complimentary reports at the links given below.
--
Biogen Inc.
--
Biogen Inc.'s stock edged lower by 4.39% to close Monday's
session at USD 272.28. The company's
shares oscillated between USD 267.00 and USD
284.00. The stock recorded a trading volume of 4.91 million
shares, which was above its 50-day daily average volume of 3.08
million shares and above its 52-week average volume of 2.00 million
shares. Over the last three days, Biogen Inc.'s shares have
declined by 8.74% and in the past one week it has moved down 8.37%.
Furthermore, over the last three months, the stock has lost 31.28%
and in the past six months, the shares have shed 36.92%. Further,
the stock is trading at a price to earnings ratio of 18.42 and a
price to book ratio of 5.09. This compares to a historical PE ratio
of 27.43 and a historical PB ratio close to 7.37. Sign up and read
the free notes on BIIB at:
http://www.aciassociation.com/BIIB.pdf
--
Depomed Inc.
--
The stock of Depomed Inc. lost 22.14% to close Monday's session
at USD 17.72. The shares of the
company moved in the range of USD
17.54 and USD 22.86. A trading
volume of 4.53 million shares was recorded, which was greater than
its 150-day daily average volume of 1.78 million shares and above
its 52-week average volume of 1.45 million shares. Over the last
five days, Depomed Inc.'s shares have declined by 36.01% and in the
past one month, it has lost 37.59%. Additionally, over the last
three months, the stock has declined 13.35% and in the past six
months, the shares have registered a loss of 22.38%. Further, the
stock is trading at a price to earnings ratio of 22.72 and a price
to book ratio of 3.09. This compares to a historical PE ratio of
7.85 and a historical PB ratio close to 2.62. Register for free on
ACI Association and access the latest research on DEPO at:
http://www.aciassociation.com/DEPO.pdf
--
Arena Pharmaceuticals Inc.
--
Arena Pharmaceuticals Inc.'s stock decreased by 5.36% to close
Monday's session at USD 2.12. The
company's shares fluctuated in the range of USD 2.04 and USD
2.24, marking a new 52-week low during the session. A total
of 3.71 million shares exchanged hands, which surpassed its 50-day
daily average volume of 2.54 million shares and was below its
52-week average volume of 4.49 million shares. Over the last three
days Arena Pharmaceuticals Inc.'s shares have declined by 17.19%
and in the past one week it has moved down 18.77%. Furthermore,
over the last three months, the stock has lost 50.70% and in the
past six months, the shares have shed 52.68%. The stock is trading
at a price to book ratio of 4.78 while the historical PB ratio is
close to 16.15. The complete research on ARNA is available for free
at: http://www.aciassociation.com/ARNA.pdf
--
Allscripts Healthcare Solutions Inc.
--
Allscripts Healthcare Solutions Inc.'s stock slipped by 4.69% to
close Monday's session at USD 12.40.
The company's shares oscillated between USD
12.31 and USD 13.06. The stock recorded a trading volume of
3.56 million shares, which was above its 50-day daily average
volume of 3.08 million shares and above its 52-week average volume
of 2.99 million shares. Over the last five days, Allscripts
Healthcare Solutions Inc.'s shares have declined by 10.31% and in
the past one month, it has lost 8.62%. In addition, over the last
three months, the stock has lost 10.98% and year to date, the
shares have shed 2.90%. The stock is trading at a price to book
ratio of 1.69 while the historical PB ratio is near to 1.79.
Additionally, the stock is trading at a price to cash flow ratio of
14.59. Free in-depth research on MDRX is available at:
http://www.aciassociation.com/MDRX.pdf
--
Amicus Therapeutics Inc.
--
Amicus Therapeutics Inc.'s stock declined 7.18% to close
Monday's session at USD 13.19. The
share price vacillated between USD 12.41 and
USD 14.18. The stock recorded a trading volume of 3.51
million shares, which was above its 50-day daily average volume of
2.13 million shares and above its 52-week average volume of 1.90
million shares. Over the last three days Amicus Therapeutics Inc.'s
shares have declined by 13.51% and in the past one week it has
moved down 18.13%. Moreover, in the last six months, the stock has
gained 20.24% and year to date, the shares have picked up 58.53%.
The complimentary notes on FOLD can be downloaded in PDF format at:
http://www.aciassociation.com/FOLD.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com